Department of General, Visceral, Vascular and Thoracic Surgery, University Medicine Berlin, Charité Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany.
Int J Colorectal Dis. 2010 Feb;25(2):245-50. doi: 10.1007/s00384-009-0819-7. Epub 2009 Nov 10.
Surgical cytoreduction of peritoneal surface malignancy of colorectal origin in combination with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) has become an established treatment approach. Only a few of animal models for scientific research on various therapeutic strategies have been described yet. The feasibility of an established rat model with a peritoneal surface malignancy from colorectal origin for treatment investigation should be examined in this study.
Peritoneal surface malignancy of colonic origin was induced in 90 male BD IX rats. Animals were randomised into six groups (15 animals per one control and five treatment groups). One treatment group underwent only surgical debulking. The animals of the other four treatment groups received additional interventions: hyperthermic intraperitoneal chemotherapy with mitomycin or gemcitabine, photodynamic therapy or taurolidine lavage. Twenty-one days after treatment, the intraperitoneal status was investigated. Tumour weight, count of tumour nodules and experimental Peritoneal Carcinosis Index (ePCI) were detected.
Extended surgical cytoreduction and additional treatments including HIPEC were feasible in this rat model. All treatment groups had a significant lower tumour weight, account of tumour nodes and ePCI if compared with the control group. Comparing the additional therapies only HIPEC with mitomycin lead to relevant tumour reduction after surgery.
This rat model is suitable for research on the multimodal treatment of peritoneal malignancies. A persisting cytoreductive effect of surgical tumour debulking could be proven. Only additional HIPEC therapy with mitomycin showed a significant tumour reduction. This animal model provides the opportunity to investigate different therapeutic strategies.
结直肠来源腹膜表面恶性肿瘤的外科减瘤术联合术中高热腹腔化疗（HIPEC）已成为一种既定的治疗方法。然而，目前仅有少数几种用于各种治疗策略的科学研究的动物模型被描述。本研究旨在检查一种结直肠来源腹膜表面恶性肿瘤的已建立大鼠模型用于治疗研究的可行性。
在 90 只雄性 BDIX 大鼠中诱导结直肠来源的腹膜表面恶性肿瘤。动物被随机分为六组（每组 15 只对照和 5 只治疗组）。一组仅接受手术减瘤。其他四组治疗组接受了额外的干预措施：用丝裂霉素或吉西他滨进行高热腹腔化疗、光动力疗法或牛磺罗定冲洗。治疗后 21 天，检查腹腔内状况。检测肿瘤重量、肿瘤结节计数和实验性腹膜癌指数（ePCI）。
在该大鼠模型中，广泛的外科减瘤术和包括 HIPEC 在内的额外治疗是可行的。与对照组相比，所有治疗组的肿瘤重量、肿瘤结节数和 ePCI 均显著降低。仅比较额外治疗，与丝裂霉素联合 HIPEC 术后可导致肿瘤明显减少。
该大鼠模型适用于腹膜恶性肿瘤的多模式治疗研究。可以证明外科肿瘤减瘤术具有持续的减瘤效果。仅丝裂霉素联合 HIPEC 的额外治疗显示出显著的肿瘤减少。该动物模型为研究不同的治疗策略提供了机会。
